NO20091659L - Fremgangsmater for behandling av disruptive oppforselsforstyrrelser - Google Patents
Fremgangsmater for behandling av disruptive oppforselsforstyrrelserInfo
- Publication number
- NO20091659L NO20091659L NO20091659A NO20091659A NO20091659L NO 20091659 L NO20091659 L NO 20091659L NO 20091659 A NO20091659 A NO 20091659A NO 20091659 A NO20091659 A NO 20091659A NO 20091659 L NO20091659 L NO 20091659L
- Authority
- NO
- Norway
- Prior art keywords
- disruptive behavior
- behavior disorders
- procedures
- treatment
- disorder
- Prior art date
Links
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 title abstract 5
- 208000035548 disruptive behavior disease Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000027691 Conduct disease Diseases 0.000 abstract 2
- 208000024196 oppositional defiant disease Diseases 0.000 abstract 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 abstract 1
- 238000011262 co‐therapy Methods 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Det beskrives en fremgangsmåte for behandling av disruptive oppførselsforstyrrelser inkludert både "Conduct Disorder" og "Oppositional Defiant Disorder" omfattende administrering til et individ som trenger det av en terapeutisk effektiv mengde av én eller flere karbamatforbindelser med formel 1 og/eller formel 2 Det beskrives videre en fremgangsmåte for behandling av disruptive oppførselsforstyrrelser inkludert både "Conduct Disorder" og "Oppositional Defiant Disorder", som inkluderer monoterapi og alternativt koterapi med minst et ytterligere psykoaktivt medisinsk virkestoff.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86313706P | 2006-10-27 | 2006-10-27 | |
PCT/US2007/081048 WO2008070277A2 (en) | 2006-10-27 | 2007-10-11 | Methods for treating disruptive behavior disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20091659L true NO20091659L (no) | 2009-05-26 |
Family
ID=39469514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20091659A NO20091659L (no) | 2006-10-27 | 2009-04-27 | Fremgangsmater for behandling av disruptive oppforselsforstyrrelser |
Country Status (19)
Country | Link |
---|---|
US (1) | US20080103127A1 (no) |
EP (1) | EP2089015B1 (no) |
JP (1) | JP2010508279A (no) |
KR (1) | KR20090088379A (no) |
CN (1) | CN101646432A (no) |
AT (1) | ATE489083T1 (no) |
AU (1) | AU2007329779A1 (no) |
BR (1) | BRPI0718318A2 (no) |
CA (1) | CA2667510A1 (no) |
CO (1) | CO6160292A2 (no) |
DE (1) | DE602007010818D1 (no) |
EA (1) | EA015690B1 (no) |
ES (1) | ES2354319T3 (no) |
IL (1) | IL198396A0 (no) |
MX (1) | MX2009004552A (no) |
NO (1) | NO20091659L (no) |
SV (1) | SV2009003241A (no) |
WO (1) | WO2008070277A2 (no) |
ZA (1) | ZA200903652B (no) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
JOP20120083B1 (ar) * | 2011-04-05 | 2021-08-17 | Otsuka Pharma Co Ltd | توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
CN114206349A (zh) | 2019-04-17 | 2022-03-18 | 指南针探路者有限公司 | 治疗神经认知障碍、慢性疼痛及减轻炎症的方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3313692A (en) * | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
US3265728A (en) * | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
PT1210118E (pt) * | 1999-08-20 | 2005-02-28 | Ortho Mcneil Pharm Inc | Composicao compreendendo um material tramadol e um farmaco anticonvulsivo |
SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
CA2439286A1 (en) * | 2001-02-27 | 2002-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating anxiety disorders |
-
2007
- 2007-10-11 KR KR1020097010725A patent/KR20090088379A/ko not_active Application Discontinuation
- 2007-10-11 DE DE602007010818T patent/DE602007010818D1/de active Active
- 2007-10-11 AT AT07871150T patent/ATE489083T1/de not_active IP Right Cessation
- 2007-10-11 JP JP2009534756A patent/JP2010508279A/ja not_active Withdrawn
- 2007-10-11 US US11/870,589 patent/US20080103127A1/en not_active Abandoned
- 2007-10-11 ES ES07871150T patent/ES2354319T3/es active Active
- 2007-10-11 EA EA200970425A patent/EA015690B1/ru not_active IP Right Cessation
- 2007-10-11 EP EP07871150A patent/EP2089015B1/en active Active
- 2007-10-11 AU AU2007329779A patent/AU2007329779A1/en not_active Abandoned
- 2007-10-11 CA CA002667510A patent/CA2667510A1/en not_active Abandoned
- 2007-10-11 MX MX2009004552A patent/MX2009004552A/es active IP Right Grant
- 2007-10-11 CN CN200780048441A patent/CN101646432A/zh active Pending
- 2007-10-11 WO PCT/US2007/081048 patent/WO2008070277A2/en active Application Filing
- 2007-10-11 BR BRPI0718318-6A patent/BRPI0718318A2/pt not_active IP Right Cessation
-
2009
- 2009-04-26 IL IL198396A patent/IL198396A0/en unknown
- 2009-04-27 SV SV2009003241A patent/SV2009003241A/es not_active Application Discontinuation
- 2009-04-27 NO NO20091659A patent/NO20091659L/no not_active Application Discontinuation
- 2009-04-29 CO CO09043278A patent/CO6160292A2/es unknown
- 2009-05-26 ZA ZA200903652A patent/ZA200903652B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010508279A (ja) | 2010-03-18 |
EA015690B1 (ru) | 2011-10-31 |
MX2009004552A (es) | 2009-11-10 |
AU2007329779A1 (en) | 2008-06-12 |
US20080103127A1 (en) | 2008-05-01 |
BRPI0718318A2 (pt) | 2013-11-26 |
WO2008070277A2 (en) | 2008-06-12 |
CN101646432A (zh) | 2010-02-10 |
ZA200903652B (en) | 2010-08-25 |
EA200970425A1 (ru) | 2009-12-30 |
DE602007010818D1 (de) | 2011-01-05 |
EP2089015B1 (en) | 2010-11-24 |
ES2354319T3 (es) | 2011-03-14 |
CA2667510A1 (en) | 2008-06-12 |
CO6160292A2 (es) | 2010-05-20 |
WO2008070277A3 (en) | 2008-08-07 |
ATE489083T1 (de) | 2010-12-15 |
EP2089015A2 (en) | 2009-08-19 |
KR20090088379A (ko) | 2009-08-19 |
SV2009003241A (es) | 2010-04-15 |
IL198396A0 (en) | 2010-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20083036L (no) | Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon | |
BRPI0408784A (pt) | método para usar um composto | |
BRPI0512220A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
BRPI0512213A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
WO2008022024A3 (en) | Imidazole amines as inhibitors of beta-secretase | |
DK1742624T3 (da) | Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet | |
NO20062704L (no) | Azabicykliske heterocykler som cannabinoide reseptormodulatorer | |
WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
NO20073831L (no) | Medikamenter for behandling eller forebygging av fibrotiske sykdommer | |
EA201300522A1 (ru) | Фармацевтические комбинации для лечения метаболических нарушений | |
CL2007003827A1 (es) | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. | |
WO2005097122A3 (en) | Method of treating schizophrenia and/or glucoregulatory abnormalities | |
BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
NO20064964L (no) | Behandling av svekket respiratorisk funksjon | |
EA200870088A1 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов и глюкозы в крови | |
NO20076357L (no) | Azabicykliske heterocykler som cannabinoid reseptor modulatorer | |
EA200802412A1 (ru) | Терапевтические комбинации для сопровождающихся болью медицинских состояний | |
NO20092018L (no) | Fremgangsmater for a behandle depresjon | |
WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
NO20091659L (no) | Fremgangsmater for behandling av disruptive oppforselsforstyrrelser | |
WO2008016640A3 (en) | Use of poloxamer for the prevention and/or treatment of heart failure | |
WO2009054957A3 (en) | Methods for diagnosis and treatment of chronic fatigue syndrome | |
EA200900269A1 (ru) | Лекарственные комбинации для лечения заболеваний дыхательных путей | |
WO2009131850A3 (en) | Pai-1 expression and activity inhibitors for the treatment of ocular disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |